Global Vigilance Masterclass: Navigating Safety in Pharmacovigilance for Drugs & Combination Products
This comprehensive three-day intensive program was designed to bridge the gap between regulatory theory and operational excellence. By focusing on the convergence of Drugs, Medical Devices, and Combination Products, the training equipped teams with the high-level technical skills required to navigate the increasingly complex global safety landscape.
Day 1: Foundations & Regulatory Frameworks
Mastering PV requirements for Devices and Combination products across global jurisdictions.
- EU MDR/IVDR & FDA 21 CFR Part 803
- Safety Database Processing
- Custom Narrative Templates
- Evaluation Checklists
Day 2: Risk Management & Strategic Surveillance
Advanced Signal Management and alignment of PSUR/DSUR with Global Risk Management Plans.
- Signal Management
- PSUR/DSUR Integration
- Trackwise/Salesforce Complaint Handling
- Global Quality Standardization
Day 3: Operational Execution & Audit Readiness
Strategic management of FSCA and Field Safety Notices with real-world audit simulations.
- FSCA & Safety Notices
- Mock Audits & Case Simulations
- Regulatory-Grade Safety Evaluations
- Report Drafting Workshop
The Value Proposition: Why Partner With Us?
Techno-Domain Approach
We bring a unique Techno-Domain approach that combines decades of clinical insight with corporate strategic leadership. Our training does not just teach regulations; it builds institutional capability.
Cross-Functional Expertise
We specialize in the "Grey Zones" where drugs and devices intersect, ensuring your team is compliant across multiple global jurisdictions simultaneously.
Audit-Centric Methodology
We move beyond passive learning by utilizing simulations and mock audits. This reduces the risk of regulatory findings and enhances the quality of safety reporting.
Digital Integration
We align safety protocols with modern tech stacks (Trackwise, Salesforce, AI-driven databases), ensuring that compliance is a seamless part of your digital workflow.
Why This is Critical in Today’s Industry
- Heightened Regulatory Rigor: With the full implementation of EU MDR and evolving FDA expectations, the threshold for "sufficient clinical evidence" and "vigilance reporting" has never been higher.
- The Rise of Combination Products: As therapy becomes more integrated (e.g., smart injectors, drug-eluting stents), the silos between Pharmacovigilance and Materiovigilance must be dismantled to avoid catastrophic compliance gaps.
- Data as a Liability and an Asset: In an era of Big Data and AI, the ability to accurately detect signals and manage risks in real-time is the difference between market leadership and a Field Safety Corrective Action.
- Global Standardization: For organizations operating across borders, harmonizing safety narratives and quality standards is essential to maintain a "Single Source of Truth" for global regulators.
Our mission is to transform your safety department from a cost center into a strategic pillar of patient safety and regulatory excellence.